Full Press Release Details
Announces Financial Results for the
Quarter Ended March 31, 2026
LAKE CITY, May 07, 2026 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform
to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2026
and provided a corporate update.
1154 for Postpartum Depression ("PPD")
| In April 2026, Lipocine announced topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D (Hamilton Depression Rating Scale) total score compared to placebo at hour 60 in the full analysis set and the primary endpoint was not met. | |
| The Phase 3 results showed LPCN 1154 to be well tolerated, demonstrating a differentiated safety profile supportive of outpatient, at-home use, with no treatment-related serious adverse events, no cases of excessive sedation or loss of consciousness, and no treatment-related discontinuations. | |
| In a post hoc analysis of participants with a history of psychiatric conditions (n=54), LPCN 1154 showed statistically significant and clinically meaningful reductions in HAM-D scores versus placebo, observed as early as hour 12 and sustained through day 30. | |
| Based on these findings, Lipocine has applied for breakthrough therapy and fast track designations for LPCN 1154 in PPD and is awaiting FDA feedback. | |
| The Company is evaluating all options regarding the potential path forward for LPCN 1154. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol in patients with a history of psychiatric conditions, development of other product candidates, strategic transactions, partnerships, and other opportunities. | |
| The Company intends to complete its full analysis of the Phase 3 trial data and plans to present results at upcoming medical conferences. For more information on the Phase 3 trial, refer to clinicaltrials.gov: NCT06979544. |
| Lipocine has an exclusive License Agreement with Verity Pharma, entered into in 2024, under which Verity Pharma has the rights to market TLANDO, its oral testosterone replacement therapy, in the United States and Canada, if approved. | |
| Lipocine has entered into additional license, supply and distribution agreements covering development and commercialization of TLANDO in other counties/ territories including Ach (Brazil), Pharmalink (GCC countries) and SPC (South Korea). | |
| Lipocine continues to explore partnering TLANDO in territories outside the U.S., Canada, South Korea, the GCC countries, and Brazil. |
Quarter Ended March 31, 2026, Financial Results
of March 31, 2026, Lipocine had $24.7 million of unrestricted cash, cash equivalents and marketable investment securities compared to
$14.9 million at December 31, 2025.
reported a net loss of $3.7 million, or ($0.52) per diluted share, for the quarter ended March 31, 2026, compared with a net loss of
$1.9 million, or ($0.35) per diluted share, for the quarter ended March 31, 2025.
company recognized royalty revenue from TLANDO sales of $119,000 during the quarter ended March 31, 2026, compared to royalty
revenue of $94,000 during the quarter ended March 31, 2025.
and development expenses were $2.8 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase
in research and development expenses was mainly the result of an increase in costs related to our LPCN 1154 clinical study in 2026.
and administrative expenses were $1.2 million and $1.1 million, respectively, for the quarters ended March 31, 2026 and 2025. The increase
in general and administrative expenses was primarily a result of an increase in various professional and consulting fees.
further details on Lipocine's financial results for the quarter ended March 31, 2026, refer to Form 10-Q filed with the SEC.
is a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery.
Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent
enablement of differentiated patient friendly oral delivery options for favorable benefit to risk profile which target large addressable
markets with significant unmet medical needs.
development pipeline includes: LPCN 1154 for the treatment of postpartum depression, LPCN 2201 for treatment of major depressive disorder,
LPCN 2101 for the treatment of epilepsy, LPCN 2203 targeted for the management of essential tremor, LPCN 2401 as an aid for improved
body composition in obesity management, LPCN 1148 targeted for the management of symptoms associated with liver cirrhosis, and LPCN 1107
our candidate for prevention of preterm birth. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed
by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism,
in adult males. For more information, please visit www.lipocine.com.
release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not historical facts regarding the potential uses and benefits of products
and product candidates, the commercial potential for product candidates, the timing of regulatory reviews and approvals and related procedures,
and potential strategic opportunities. Investors are cautioned that all such forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital
to complete the development processes for our product candidates or we may decide to allocate our available capital to other product
candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our assets, safety and efficacy
studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of
a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical
and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval
process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results
and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's
products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports
on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update
or revise publicly any forward-looking statements contained in this release, except as required by law.
further information:
INC. AND SUBSIDIARIES
Consolidated Balance Sheets
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,015,608 | $ | 5,205,842 | ||||
| Marketable investment securities | 19,713,463 | 9,724,545 | ||||||
| Accrued interest income | 111,411 | 14,189 | ||||||
| License fee and royalties receivable | 119,397 | 1,145,390 | ||||||
| Prepaid and other current assets | 285,055 | 787,600 | ||||||
| Total current assets | 25,244,934 | 16,877,566 | ||||||
| Property and equipment, net of accumulated depreciation of $ 1,298,893 and $1,284,079 respectively | 89,479 | 104,293 | ||||||
| Other assets | 23,753 | 23,753 | ||||||
| Total assets | $ | 25,358,166 | $ | 17,005,612 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,562,728 | $ | 971,822 | ||||
| Accrued expenses | 645,115 | 1,236,374 | ||||||
| Deferred revenue | 320,000 | 320,000 | ||||||
| Total current liabilities | 2,527,843 | 2,528,196 | ||||||
| Total liabilities | 2,527,843 | 2,528,196 | ||||||
| Stockholders' equity: | ||||||||
| Common stock, par value $0.0001 per share, 75,000,000 shares authorized; 7,475,451 and 6,158,779 issued and 7,475,115 and 6,158,443 outstanding, respectively | 9,076 | 8,944 | ||||||
| Additional paid-in capital | 235,937,414 | 223,901,106 | ||||||
| Treasury stock at cost, 336 shares | (40,712 | ) | (40,712 | ) | ||||
| Accumulated other comprehensive income | (7,194 | ) | 4,445 | |||||
| Accumulated deficit | (213,068,261 | ) | (209,396,367 | ) | ||||
| Total stockholders' equity | 22,830,323 | 14,477,416 | ||||||
| Total liabilities and stockholders' equity | $ | 25,358,166 | $ | 17,005,612 |
INC. AND SUBSIDIARIES
Consolidated Statements of Operations and Comprehensive Loss
| Three Months Ended March 31, | ||||||||
| 2026 | 2025 | |||||||
| Revenues: | ||||||||
| Royalty revenue | 119,397 | 93,864 | ||||||
| Total revenues | 119,397 | 93,864 | ||||||
| Operating expenses: | ||||||||
| Research and development | 2,764,394 | 1,061,571 | ||||||
| General and administrative | 1,204,467 | 1,122,477 | ||||||
| Total operating expenses | 3,968,861 | 2,184,048 | ||||||
| Operating loss | (3,849,464 | ) | (2,090,184 | ) | ||||
| Other income: | ||||||||
| Interest and investment income | 177,570 | 225,511 | ||||||
| Total other income | 177,570 | 225,511 | ||||||
| Loss before income tax expense | (3,671,894 | ) | (1,864,673 | ) | ||||
| Income tax expense | - | (200 | ) | |||||
| Net loss attributable to common shareholders Net loss attributable to common shareholders | $ | (3,671,894 | ) | $ | (1,864,873 | ) | ||
| Basic loss per share attributable to common stock | $ | (0.54 | ) | $ | (0.35 | ) | ||
| Weighted average common shares outstanding, basic | 6,795,002 | 5,348,557 | ||||||
| Diluted loss per share attributable to common stock | $ | (0.54 | ) | $ | (0.35 | ) | ||
| Weighted average common shares outstanding, diluted | 6,795,002 | 5,348,557 | ||||||
| Comprehensive loss: | ||||||||
| Net loss | $ | (3,671,894 | ) | $ | (1,864,873 | ) | ||
| Net unrealized loss on marketable investment securities | (11,639 | ) | (3,617 | ) | ||||
| Comprehensive loss | $ | (3,683,533 | ) | $ | (1,868,490 | ) |